Skin cancer vaccine BLA submitted by June 30, 2027?

The strongest reason to favor Yes is that intismeran autogene is already beyond early development and sits in a registrational posture, which makes a BLA submission by mid-2027 feasible if the ongoing program delivers. Moderna and Merck are both highly capable sponsors with the regulatory, clinical, and manufacturing infrastructure to turn a positive pivotal readout into a filing faster than a smaller company could, and the event does not require approval, only submission or FDA acceptance.

That said, this is still a novel, individualized cancer vaccine program, and novelty cuts both ways. A BLA filing is only likely if the phase 3 data are persuasive enough to support licensure, the CMC package is ready, and the companies believe the risk of filing is acceptable rather than premature. Because the product is personalized, scaling manufacturing, release testing, and consistency across patients are real operational hurdles that can delay a submission even when the science is encouraging.

The current market price of 86.5 percent implies substantial confidence that the key milestones will land on time. I think that confidence is somewhat aggressive, not because the program looks weak, but because the remaining path still depends on several timing-sensitive events that can slip by a quarter or two. With only about ten months remaining, even a modest delay in data readout, label strategy, or manufacturing readiness could push the filing past the deadline, so I would discount the market a bit while still treating Yes as the more likely outcome.